BCRX Q2 2021 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$50M+1640.1% YoY

Gross Profit

$50M99.3% margin

Operating Income

-$30M-59.2% margin

Net Income

-$43M-86.5% margin

EPS (Diluted)

$-0.24

QoQ Revenue Growth

+162.1%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$26M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$277M

Total Liabilities

$383M

Stockholders' Equity

-$106M

Cash & Equivalents

$210M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$50M	$3M	+1640.1%
Gross Profit	$50M	$3M	+1628.2%
Operating Income	-$30M	-$39M	+23.2%
Net Income	-$43M	-$39M	-11.9%

Revenue Segments

Collaborative and Other Research and Development

$1M100%